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Inactivation of Notch signaling  
in the renal collecting duct causes 
nephrogenic diabetes insipidus  
in mice
Jeong et al., J Clin Invest 2009; 119: 3290–3300; doi:10.1172/JCI38416
The collecting duct of the mammalian kidney contains two cell 
types, principal and intercalated. Each of these cells is special-
ized for some specific transport function; the principal cell is 
concerned with Na, K, and water transport, and the intercalated 
cell is concerned with H+ and HCO3 transport. The most inter-
esting question regarding the development of a tissue such as the 
collecting tubule is how this seemingly random distribution of 
cell types comes about. Most ideas of cell specifications and cell 
fate are based on external signals expressed by other cells, often 
in a gradient manner. But how does such a ‘salt and pepper’ dis-
tribution develop? Here, the collecting tubule is similar to some 
other vertebrate tissues such as fish or amphibian skin and fish 
gills, which also contain intercalated cells. Research in zebrafish 
skin and pronephros suggests that the Notch signaling pathway 
is involved in the specification of these two cell types. Jeong et 
al. studied the mammalian kidney using a conditional knockout 
of Mib1, a critical intermediate in the Notch signaling pathway 
only, in the collecting duct of mouse kidneys. Notch is a trans-
membrane protein receptor whose ligand Jagged is also a mem-
brane protein. Hence, the signaling implies that one cell directly 
interacts with a neighboring cell to change its fate, a pro cess 
termed lateral inhibition. Once the ligand engages the receptor, 
a proteolytic event occurs and leads to release of the C-terminal 
intracellular domain of Notch (NICD), which then traffics to the 
nucleus, where it exerts its role as a transcriptional regulator. The 
authors found that deletion of Mib1 resulted in a dramatic pheno-
type: the proportion of intercalated cells in the collecting tubule 
increased dramatically. The decrease in the number of principal 
cells caused polyuria and diabetes insipidus (DI), presumably due 
to a reduction in the number of aquaporin-2-containing cells. 
As often happens with congenital DI, the polyuria in the mice 
induced hydronephrosis. The authors overexpressed the NICD 
in these mutant mice with equally dramatic results, as all of the 
cells became principal cells.
These studies clarify the development and differentiation of the 
collecting duct. This structure develops from the ureteric bud, 
an outgrowth of the wolffian duct. Hence, one can postulate that 
the original ureteric bud cell, when it expresses an active Notch/
Jagged, results in a strong positive signal and causes this undif-
ferentiated cell to convert to a mature principal cell. Whether the 
intercalated cell requires another signal or has a default pathway to 
become a β type, which then converts to the α type, remains to be 
demonstrated. Certainly, these authors have provided a compel-
ling story for the initial stage of differentiation of the collecting 
duct of the mammalian kidney.
Qais Al-Awqati
Why don’t statins always work?
Karumanchi and Thadhani, Nat Med 2010; 16: 38–40; doi:10.1038/nm0110-38
Dialysis patients have mortality comparable to, or worse than, 
that seen with many cancers, and approximately 50% of this 
increased mortality is due to cardiovascular diseases. Clinical 
studies have shown that statins do not work in this population. 
Karumanchi and Thadhani demonstrate how this clinical find-
ing is spurring research into the biological mechanisms behind 
cardiovascular death with kidney disease. One of the biggest 
success stories in the management of coronary artery disease, 
statins emerged from an understanding of how the low-density 
lipoprotein–cholesterol (LDL-cholesterol) pathway contributed 
to atherosclerosis and how inhibition of a key enzyme in this 
pathway markedly lowered LDL-cholesterol levels and cardio-
vascular event counts. Hemodialysis or peritoneal patients do 
not seem to benefit from these drugs.
Wanner et al.1 and Fellström et al.2 showed that statins conferred 
no major reduction in the composite cardiovascular end points in 
dialysis patients, notwithstanding a substantial reduction in LDL-
cholesterol. Their trials were among the first set of negative results 
for statins with respect to prevention of cardio vascular death in 
high-risk populations. However, unlike the general population, 
individuals undergoing chronic dialysis have cholesterol levels 
inversely related to risk of mortality. The average LDL-cholesterol 
concentration at enrollment in the AURORA study was 2.57 mmol/l 
(99 mg/dl), well within the recommended range even for high-risk 
individuals. The low cholesterol levels, noted at baseline in subjects 
with end-stage renal disease, may have been a reflection of the sys-
temic malnutrition often seen in these subjects.3 Karumanchi and 
Thadhani suggest three major reasons for death in this population: 
accelerated atherosclerosis, left ventricular hypertrophy, and ure-
mic cardiomyopathy (Figure). They propose that scientists develop 
animal models of uremic heart disease that more accurately cap-
ture the cardiac phenotypes noted in uremia, and, in particular, 
the occurrence of sudden cardiac deaths. Detailed pheno typic and 
autopsy studies are still needed to rigorously document cardio-
vascular pathology and find, for example, the percentage of patients 
Summary of the pathogenesis of cardiovascular disease in uremia. 
ADMA, asymmetrical dimethyarginine; NO, nitric oxide.
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on dialysis having microvessel disease or interstitial fibrosis in the 
heart, as well as to identify the predominant form of heart pathol-
ogy. Finally, unique biomarkers that may predict adverse cardio-
vascular events, such as carbamoylation of LDL, are needed for use 
in proof-of-concept clinical studies.
The history of negative or neutral clinical trials in subjects on 
dialysis should encourage rather than discourage active research. 
This research supports the study of alternative pathways with 
strong biological rationale.
Mark De Broe
1N Engl J Med 2005; 353: 238–248; erratum 2005; 353: 1640. 2N Engl J Med 2009; 360: 
1395–1407. 3JAMA 2004; 291: 451–459. 
The Bypass Angioplasty 
Revascularization Investigation 
2 Diabetes randomized trial of 
different treatment strategies in 
type 2 diabetes mellitus with stable 
ischemic heart disease
Chaitman et al., Circulation 2009; 120: 2529–2540; doi:10.1161/
CIRCULATIONAHA.109.913111
The number of dedicated trials testing therapies in patients with 
kidney disease is low despite the fact that patients with chronic 
kidney disease (CKD) and end-stage renal disease (ESRD) have a 
greater burden of heart disease than patients with normal kidney 
function. Observational studies suggest that patients with CKD 
or ESRD may have better outcomes than patients with normal 
kidney function with coronary artery bypass grafting (CABG) as 
compared with percutaneous coronary intervention (PCI).1,2 In 
question is whether one or both of these strategies offer an advan-
tage over intensive medical management for these patients. The 
BARI 2D trial used a two-by-two factorial design randomizing 
2368 patients to an early versus only-if-necessary revasculariza-
tion strategy (revascularization versus intensive medical therapy 
(IMT))1; and a glycemic control strategy of insulin sensitization 
versus insulin provision, both to a target hemoglobin A1c of 
<7%.2 When the treatment groups were compared, the 5-year 
all-cause mortality rates did not differ between revasculariza-
tion (11.7%) and IMT (12.2%) or between insulin sensitization 
(11.8%) and insulin provision (12.2%). While this trial did not 
enroll patients with severe CKD or ESRD, a similar trend in sud-
den death was seen. Of the 316 deaths, 136 were due to cardiac 
causes, 69.1% of them adjudicated as sudden death. Stratified 
on type of revascularization, the authors observed dissimilar 
rates of cardiac death or myocardial infarction (MI). While the 
authors saw no differences in the rates of cardiac death or MI in 
the patients in the PCI stratum, they found that patients in the 
CABG stratum undergoing revascularization experienced an 
MI event significantly less frequently than did those in the IMT 
group (10% versus 17.6%). All-cause death and nonfatal MI was 
similarly less frequent (21.1% versus 29.2%).
The authors’ conclusions may be generalized to our popu-
lation. Given that the median glomerular filtration rate was 
approximately 70 ml/min (ref. 3), a proportion of patients had 
either mild or moderate CKD. This study’s conclusions would 
support those of previous studies, if the results are similar 
among the subgroup with CKD. Interestingly, the large burden 
of sudden death was similar in this population to that of patients 
with ESRD. Until more dedicated trials are done, this research 
supports a limited clinical utility of PCI in our population of 
patients with multiple comorbidities.
Lynda Szczech 
1Kidney Int 2001; 60: 292–299. 2J Am Soc Nephrol 2003; 14: 2373–2380. 3NEJM 2009; 
360: 2503–2515.
Autophagy is a renoprotective 
mechanism during in vitro hypoxia 
and in vivo ischemia–reperfusion 
injury
Jiang et al., Am J Pathol advance online publication, 14 January 2010, 
doi:10.2353/ajpath.2010.090594
Autophagy, a pathway for removing cytosolic and membrane-
associated proteins as well as entire cell organelles in an attempt 
to salvage cellular proteins during starvation and other types of 
tissue stress, is increasingly recognized as a mechanism to control 
cellular homeostasis under a large variety of stress situations. As 
such, autophagy plays a significant role in neuro degenerative, 
cardiac, and liver diseases. In the kidney, increased autophagy 
has been shown during ischemia–reperfusion injury, transplant 
ischemia, and cisplatinum and cyclosporine toxicity. Cellular 
and tissue stress induces autophagy, which may either contrib-
ute to cell death or serve as a cell survival mechanism. Using 
in vitro and in vivo models of ischemia–reperfusion, Jiang et 
al. examined autophagy and its pathological role in renal-cell 
injury. They found that hypoxia (1% O2) induced autophagy in 
cultured renal proximal tubular cells. Blockade of autophagy, by 
pharmacological inhibition or by knock-down of Beclin-1 and 
ATG5 (two key autophagic genes), sensitized the tubular cells to 
hypoxia-induced apoptosis. In an in vitro model of ischemia–
reperfusion, suppression of autophagy also enhanced apoptosis. 
In vivo, autophagy was induced in kidney tissues during renal 
ischemia–reperfusion in mice. Although not obvious during the 
ischemia period, autophagy was significantly enhanced during 
reperfusion. Inhibition of autophagy worsened renal ischemia–
reperfusion injury, as determined by renal function, histology, 
and tubular apoptosis.
These studies support the notion, deduced from experimental 
tissue damage in other organs, that autophagy may be an initial 
process to protect cells from injury by removing damaged cellular 
components, including mitochondria. As autophagy is upregu-
lated by inhibition of the mTOR pathway, inhibitors of this path-
way, such as rapamycin, may prove beneficial in a variety of tissue 
injuries when autophagy plays a role.
Detlef Schlöndorff
